Phenotype-Genotype Correlation in Familial Breast Cancer

Familial breast cancer accounts for a small but significant proportion of breast cancer cases worldwide. Identification of the candidate genes is always challenging specifically in patients with little or no family history. Therefore, a multidisciplinary team is required for the proper detection and further management of these patients. Pathologists have played a pivotal role in the cataloguing of genotypic-phenotypic correlations in families with hereditary cancer syndromes. These efforts have led to the identification of histological and phenotypic characteristics that can help predict the presence or absence of germline mutations of specific cancer predisposition genes. However, the panoply of cancer phenotypes associated with mutations of genes other than in BRCA1 is yet to be fully characterised; in fact, many cancer syndromes, germline mutations and gene sequence variants are under investigation for their possible morphological associations. Here we review the current understanding of phenotype-genotype correlation in familial breast cancer.

[1]  J. Satagopan,et al.  Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. , 2007, Cancer research.

[2]  Y. Shiloh.  ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.

[3]  F. Couch,et al.  Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. , 2004, American journal of human genetics.

[4]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[5]  Bing Xia,et al.  PALB2/FANCN: recombining cancer and Fanconi anemia. , 2010, Cancer research.

[6]  D. Huntsman,et al.  Characterization of a Recurrent Germ Line Mutation of the E-Cadherin Gene: Implications for Genetic Testing and Clinical Management , 2005, Clinical Cancer Research.

[7]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[8]  I. Ellis,et al.  Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype , 2008, British Journal of Cancer.

[9]  F. Bray,et al.  The changing global patterns of female breast cancer incidence and mortality , 2004, Breast Cancer Research.

[10]  T. Smyrk,et al.  An update of HNPCC (Lynch syndrome). , 1997, Cancer genetics and cytogenetics.

[11]  B. Spencer‐Dene,et al.  A Crucial Role for Fibroblast Growth Factor Signaling in Embryonic Mammary Gland Development , 2004, Journal of Mammary Gland Biology and Neoplasia.

[12]  Jong-Soo Lee,et al.  hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response , 2000, Nature.

[13]  M. Daly,et al.  Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer , 2010, PLoS Genetics.

[14]  S. Lakhani,et al.  Aberrant Expression of E-cadherin in Lobular Carcinomas of the Breast , 2008, The American journal of surgical pathology.

[15]  L. Esserman,et al.  Ductal carcinoma in situ in BRCA mutation carriers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[17]  J. Peto,et al.  p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours , 1998, Oncogene.

[18]  Daniel J Schaid,et al.  Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers , 2003, Cancer.

[19]  Alun Thomas,et al.  Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. , 2009, American journal of human genetics.

[20]  D. Birnbaum,et al.  Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. , 2000, Cancer research.

[21]  I. Andrulis,et al.  Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. , 1999, Journal of the National Cancer Institute.

[22]  R. Seruca,et al.  Microsatellite instability in medullary breast carcinomas , 1999, International journal of cancer.

[23]  K. Hemminki,et al.  CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk , 2002, International journal of cancer.

[24]  M. Stratton,et al.  The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  J. Boyd,et al.  Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. , 1997, Cancer research.

[26]  T. Smyrk,et al.  Tumor‐infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma , 2001, Cancer.

[27]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Benítez,et al.  Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer , 2006, Breast Cancer Research and Treatment.

[29]  Michael O Woods,et al.  A new variant database for mismatch repair genes associated with Lynch syndrome , 2007, Human mutation.

[30]  B. Fernandez,et al.  Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. , 2007, JAMA.

[31]  T. Halazonetis,et al.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.

[32]  F. Sarkar,et al.  Correlation Between p53 Immunostaining Patterns and Gene Sequence Mutations in Breast Carcinoma , 1996, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[33]  W. Foulkes,et al.  Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria , 2004, Journal of Medical Genetics.

[34]  H. Tsou,et al.  Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. , 1998, Human pathology.

[35]  S. Tommasi,et al.  Molecular and in silico analysis of BRCA1 and BRCA2 variants. , 2008, Mutation research.

[36]  P. Depowski,et al.  Loss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer , 2001, Modern Pathology.

[37]  E. Levy-Lahad,et al.  Fanconi anemia and breast cancer susceptibility meet again , 2010, Nature Genetics.

[38]  J. W. Kim,et al.  Expression of hMSH2 and hMLH1 in colorectal carcinomas with microsatellite instability. , 1998, Pathology, research and practice.

[39]  F. Couch,et al.  Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Copetti,et al.  High RAD51 mRNA expression characterize estrogen receptor‐positive/progesteron receptor‐negative breast cancer and is associated with patient's outcome , 2011, International journal of cancer.

[41]  M. Gilcrease.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009 .

[42]  J. Kładny,et al.  Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2009, Breast Cancer Research and Treatment.

[43]  Peter Kraft,et al.  Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.

[44]  D. Horsman,et al.  Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. , 2008, Cancer research.

[45]  M. Espié,et al.  Cowden disease and Lhermitte Duclos disease, markers of breast carcinoma: report of two patients. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  A. Duval,et al.  Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. , 2002, Gastroenterology.

[47]  D. Stoppa-Lyonnet,et al.  Intraductal component and BRCA1 associated breast cancer , 1996, The Lancet.

[48]  Shu Ichihara,et al.  Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists , 2011, Modern Pathology.

[49]  S. Bull,et al.  Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors , 2008, Breast Cancer Research and Treatment.

[50]  T. Mak,et al.  Brca2 Deficiency Does Not Impair Mammary Epithelium Development but Promotes Mammary Adenocarcinoma Formation in p53+/− Mutant Mice , 2004, Cancer Research.

[51]  D. Stoppa-Lyonnet,et al.  ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy , 2009, Breast Cancer Research and Treatment.

[52]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[53]  Baljit Singh,et al.  Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus , 1998, Genes, chromosomes & cancer.

[54]  M. Paz,et al.  Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families , 2007, Modern Pathology.

[55]  A. Ashworth,et al.  Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas , 2008, The Journal of pathology.

[56]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[57]  J. Benítez,et al.  Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information , 2007, Human mutation.

[58]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[59]  M. Gatei,et al.  Role for ATM in DNA damage-induced phosphorylation of BRCA1. , 2000, Cancer research.

[60]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[61]  R. Tollenaar,et al.  Correspondence re: A. Müller et al., Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res., 62: 1014-1019, 2002. , 2003, Cancer research.

[62]  A. Ashworth,et al.  BRCA1 dysfunction in sporadic basal-like breast cancer , 2007, Oncogene.

[63]  K. Kinzler,et al.  Clues to the pathogenesis of familial colorectal cancer. , 1993, Science.

[64]  Douglas F. Easton,et al.  Common Genetic Variation in Candidate Genes and Susceptibility to Subtypes of Breast Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[65]  J. Palazzo,et al.  Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. , 2002, Cancer research.

[66]  A. Lopes,et al.  Frequency of extra-colonic tumors in hereditary nonpolyposis colorectal cancer (HNPCC) and familial colorectal cancer (FCC) Brazilian families: An analysis by a Brazilian Hereditary Colorectal Cancer Institutional Registry , 2004, Familial Cancer.

[67]  P. Westenend,et al.  Breast cancer in an MSH2 gene mutation carrier. , 2005, Human pathology.

[68]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[69]  A. Auerbach,et al.  Fanconi anemia and its diagnosis. , 2009, Mutation research.

[70]  K. Byth,et al.  Histopathological features of breast cancer in carriers of ATM gene variants , 2006, Histopathology.

[71]  S. Bull,et al.  CK8/18 expression, the basal phenotype, and family history in identifying BRCA1‐associated breast cancer in the Ontario site of the Breast Cancer Family Registry , 2011, Cancer.

[72]  I. Siccama,et al.  Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data , 2006, Journal of Clinical Pathology.

[73]  O. Olopade,et al.  Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers , 2010, Journal of Medical Genetics.

[74]  H. Höfler,et al.  Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. , 1999, The American journal of pathology.

[75]  A. Vargas,et al.  Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges. , 2011, Human pathology.

[76]  Jing Chen,et al.  Characterization of Tumor-associated Chk2 Mutations* , 2001, The Journal of Biological Chemistry.

[77]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[78]  D. Evans,et al.  Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations , 2009, Clinical genetics.

[79]  H. Morreau,et al.  Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? , 2001, American journal of human genetics.

[80]  Catherine Bonaïti-Pellié,et al.  2009 version of the Chompret criteria for Li Fraumeni syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  J. Klijn,et al.  Association of rare MSH6 variants with familial breast cancer , 2010, Breast Cancer Research and Treatment.

[82]  Charis Eng,et al.  PTEN: One Gene, Many Syndromes , 2003, Human mutation.

[83]  A. Coatesworth,et al.  Cowden disease: a review , 2007, International journal of clinical practice.

[84]  G. Farshid,et al.  Morphology of Breast Cancer as a Means of Triage of Patients for BRCA1 Genetic Testing , 2006, The American journal of surgical pathology.

[85]  F. Couch,et al.  Common breast cancer predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers , 2008 .

[86]  P. Nederlof,et al.  High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. , 2009, Cancer research.

[87]  G. Casey,et al.  Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers , 2001, Molecular pathology : MP.

[88]  R. Scott,et al.  Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. , 2001, American journal of human genetics.

[89]  Lance D. Miller,et al.  A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor–Positive Tumors , 2006, Clinical Cancer Research.

[90]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[91]  A. Whittemore,et al.  BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays , 2007, The American journal of surgical pathology.

[92]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[93]  X. H. Chen,et al.  Germline mutational analysis of CDH1 and pathologic features in familial cancer syndrome with diffuse gastric cancer/breast cancer proband in a Chinese family. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[94]  I. Temple,et al.  Cowden syndrome and Bannayan–Riley–Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers , 2007, Journal of Medical Genetics.

[95]  M. Vinceti,et al.  Comparison between genotype and phenotype identifies a high‐risk population carrying BRCA1 mutations , 2000, Genes, chromosomes & cancer.

[96]  H. Hibshoosh,et al.  Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas , 1998, Oncogene.

[97]  Lesley McGuffog,et al.  Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.

[98]  J. Sng,et al.  Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  J. Slingerland,et al.  PTEN deficiency: a role in mammary carcinogenesis , 2001, Breast Cancer Research.

[100]  M. Daly,et al.  Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer , 2010, PLoS genetics.

[101]  L. Bégin,et al.  Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer , 2005, Clinical Cancer Research.

[102]  F. Couch,et al.  RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. , 2007, American journal of human genetics.

[103]  P. Sung,et al.  Mechanism of eukaryotic homologous recombination. , 2008, Annual review of biochemistry.

[104]  M. Gorospe,et al.  miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. , 2011, Molecular cell.

[105]  J. Reis-Filho,et al.  Hereditary breast cancer: from molecular pathology to tailored therapies , 2008, Journal of Clinical Pathology.

[106]  Å. Borg,et al.  Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors , 2005, Modern Pathology.

[107]  A. Vincent-Salomon,et al.  Low expression of bcl-2 in Brca1-associated breast cancers , 2000, British Journal of Cancer.

[108]  P. Bourne,et al.  Mismatch Repair Genes hMLH1 and hMSH2 May Not Play an Essential Role in Breast Carcinogenesis , 2007, International journal of surgical pathology.

[109]  H. Nevanlinna,et al.  The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer , 2008, Oncogene.

[110]  S. Lakhani,et al.  Pathology of hereditary breast cancer. , 2010, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[111]  A. Sigurdsson,et al.  Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer , 2008, Nature Genetics.

[112]  A. D’Andrea,et al.  Susceptibility pathways in Fanconi's anemia and breast cancer. , 2010, The New England journal of medicine.

[113]  G. Hortobagyi,et al.  Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  Hugo M. Horlings,et al.  Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets , 2009, Oncogene.

[115]  Andrew R. Green,et al.  CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome , 2008, Breast Cancer Research and Treatment.

[116]  Jing Zhang,et al.  Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer , 2010, Breast Cancer Research and Treatment.

[117]  J. Cigudosa,et al.  Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers , 2005, Breast Cancer Research and Treatment.

[118]  P. Devilee,et al.  A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history , 2009, Breast Cancer Research.

[119]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[120]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[121]  H. Meijers-Heijboer,et al.  TP53 germline mutation testing in 180 families suspected of Li–Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes , 2010, Journal of Medical Genetics.

[122]  S. Ethier,et al.  Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. , 2004, Molecular cancer research : MCR.

[123]  Petra M. Nederlof,et al.  Analysis of PALB2/FANCN-associated breast cancer families , 2007, Proceedings of the National Academy of Sciences.

[124]  Curtis C. Harris,et al.  Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis , 2001, Nature Genetics.

[125]  A. Ashworth,et al.  Targeted therapy for cancer using PARP inhibitors. , 2008, Current opinion in pharmacology.

[126]  P. Chappuis,et al.  A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer , 2002, Journal of medical genetics.

[127]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  J. Potter,et al.  Lynch Syndrome–Associated Breast Cancers: Clinicopathologic Characteristics of a Case Series from the Colon Cancer Family Registry , 2010, Clinical Cancer Research.

[129]  C Eng,et al.  Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. , 1998, Human molecular genetics.

[130]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[131]  D. Gudbjartsson,et al.  Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer , 2007, Nature Genetics.

[132]  G. Bevilacqua,et al.  Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[133]  H. Sugimura,et al.  Identification and characterization of a novel germline p53 mutation in a patient with glioblastoma and colon cancer , 2009, International journal of cancer.

[134]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[135]  Á. Carracedo,et al.  Beyond BRCA1 and BRCA2 wild‐type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN , 2010, Clinical genetics.

[136]  P. J. Welch,et al.  Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[137]  C Caldas,et al.  Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. , 2001, Gastroenterology.

[138]  M. Beckmann,et al.  Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[139]  H. Tsao.  Update on familial cancer syndromes and the skin. , 2000, Journal of the American Academy of Dermatology.

[140]  M. Look,et al.  Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families , 2011, Breast Cancer Research and Treatment.

[141]  J. Fraumeni,et al.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.

[142]  S. Gruber,et al.  Phenotype of Microsatellite Unstable Colorectal Carcinomas: Well‐Differentiated and Focally Mucinous Tumors and the Absence of Dirty Necrosis Correlate With Microsatellite Instability , 2003, The American journal of surgical pathology.

[143]  D. Steinemann,et al.  Histopathological criteria and selection algorithms for BRCA1 genetic testing. , 2009, Cancer genetics and cytogenetics.

[144]  K. Hemminki,et al.  Morphological types of breast cancer in family members and multiple primary tumours: is morphology genetically determined? , 2002, Breast Cancer Research.

[145]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[146]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[147]  M. Stratton.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[148]  P. Miron,et al.  Germline E-cadherin mutations in familial lobular breast cancer , 2007, Journal of Medical Genetics.

[149]  J. Kirk,et al.  Breast cancer immunohistochemistry can be useful in triage of some HNPCC families , 2009, Familial Cancer.

[150]  J. Douglas,et al.  Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America. , 2010, Cancer genetics and cytogenetics.

[151]  I. Ellis,et al.  Expression of BRCA1 protein in breast cancer and its prognostic significance. , 2008, Human pathology.

[152]  S. Thibodeau,et al.  Microsatellite instability in hereditary and sporadic breast cancers , 2003, International journal of cancer.

[153]  P. Ongusaha,et al.  BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest , 2003, Oncogene.

[154]  J. Lubiński,et al.  Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  D. Birnbaum,et al.  Novel indications for BRCA1 screening using individual clinical and morphological features , 1999, International journal of cancer.

[156]  M. Schutte,et al.  Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant , 2004, Journal of Medical Genetics.

[157]  J. Peterse,et al.  Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  J. Cigudosa,et al.  Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[159]  W. Thompson,et al.  The genetic attributable risk of breast and ovarian cancer , 1996, Cancer.

[160]  J. Benítez,et al.  The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features , 2009, Breast Cancer Research and Treatment.

[161]  Harry J de Koning,et al.  BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  Daniel J Sargent,et al.  Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[164]  N. Rahman,et al.  A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations , 2010, Journal of Medical Genetics.

[165]  O. Olopade,et al.  Male breast cancer in Cowden syndrome patients with germlinePTEN mutations , 2001, Journal of medical genetics.

[166]  Franca Fraternali,et al.  Mutation of the RAD51C gene in a Fanconi anemia–like disorder , 2010, Nature Genetics.

[167]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[168]  M. Lovett,et al.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.

[169]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[170]  J. Reis-Filho,et al.  Absence of microsatellite instability in mucinous carcinomas of the breast. , 2010, International journal of clinical and experimental pathology.

[171]  J. Hopper,et al.  Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants , 2005, Journal of Medical Genetics.

[172]  A. Richardson,et al.  Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers , 2009, The American journal of surgical pathology.

[173]  L. Bégin,et al.  The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer , 2004, Cancer Research.

[174]  Pawel Domagala,et al.  Immunophenotypic predictive profiling of BRCA1-associated breast cancer , 2010, Virchows Archiv.

[175]  J. Varley.  Germline TP53 mutations and Li‐Fraumeni syndrome , 2003, Human mutation.

[176]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[177]  A. Vincent-Salomon,et al.  High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. , 2009, Cancer research.

[178]  J. Varley,et al.  Relative frequency and morphology of cancers in carriers of germline TP53 mutations , 2001, Oncogene.

[179]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[180]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[181]  F. Couch,et al.  Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[182]  Yushui Ma,et al.  Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer , 2010, Breast Cancer Research and Treatment.

[183]  J. Hopper,et al.  Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. , 2006, Cancer research.

[184]  Jung-Sik Kim,et al.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.

[185]  L. Albarello,et al.  Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences , 2000, Virchows Archiv.

[186]  A. Ashworth,et al.  PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors , 2010, Science Translational Medicine.

[187]  J. Rüschoff,et al.  Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. , 1997, Cancer research.

[188]  Nazneen Rahman,et al.  The emerging landscape of breast cancer susceptibility , 2007, Nature Genetics.

[189]  M. Beckmann,et al.  Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation , 2003, The British journal of dermatology.

[190]  K. Byth,et al.  Familial concordance of breast cancer pathology as an indicator of genotype in multiple‐case families , 2010, Genes, chromosomes & cancer.

[191]  E. Lerma,et al.  Evaluation of breast involvement in relation to Cowden syndrome: a radiological and clinicopathological study of patients with PTEN germ-line mutations , 2006, European Radiology.

[192]  W. Dinjens,et al.  E‐cadherin—catenin cell—cell adhesion complex and human cancer , 2000, The British journal of surgery.

[193]  U. Jensen,et al.  Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome , 2010, Breast Cancer Research and Treatment.

[194]  D. Venter,et al.  The pathology of inherited breast cancer , 2002, Pathology.